# Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients

> **NCT00170833** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 80 (—)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00170833
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2005-11
- **Final completion:** —
- **Target enrollment:** 80 (—)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170833, "Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00170833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*